CINCINNATI, Jan 27 (Bernama) -- Meridian Bioscience, Inc. (NASDAQ:VIVO)
today announced that it has received the CE Mark for illumigene®
Malaria, a novel, highly accurate test developed by Meridian with the
technical assistance of the Centers for Disease Control and Prevention
(CDC) and Cheikh Anta Diop University of Dakar, Senegal. The test is up
to 80,000 times more sensitive at detecting the malaria parasite than
conventional tests, potentially revolutionizing malaria diagnosis and
establishing a new gold standard. Using innovative molecular LAMP
technology, illumigene results are available in under one hour, and the
test is easy to use as it does not rely on high level technical
expertise. This is a major step forward for people with malaria as
faster, more accurate diagnoses should lead to prompt treatment and
better outcomes.
illumigene Malaria will be distributed in the European, Middle Eastern
and African regions by Meridian Bioscience Europe and in additional
international markets by the Company's global distribution network.
http://www.bernama.com/bernama/v8/newsindex.php?id=1210583
No comments:
Post a Comment